Scientific Advisory Board

Prof Dr WJ van Venrooij and Prof Dr GJM Pruijn, are world leaders in the field of autoimmune diseases. They have successfully developed the well-established diagnostic target for rheumatoid arthritis (CCP), which now forms the basis for marketed diagnostics for RA worldwide.

Prof Walter van Venrooij

Professor Dr Walther van Venrooij

Co-Founder

Professor van Venrooij did his PhD in 1968 at the University of Utrecht, The Netherlands and a post-doctoral research study at Harvard Medical School (Boston). After that he became a full professor of Biochemistry at the Radboud University of Nijmegen, The Netherlands. His research primarily focused on autoimmune diseases like rheumatoid arthritis (RA), SLE and myositis. His group was the first to publish that most patients with RA have antibodies directed to citrullinated antigens (1998), a discovery which led his team to develop the CCP2 test, now a serologic criterion for classifying rheumatoid arthritis. In 2002 he received the Carol Nachmann Award for his research on autoimmune diseases and in 2004 he received the Honorary Medal from the Netherlands Society for Rheumatology.

Prof Dr Ger Pruijn, ModiQuest founder

Professor Dr Ger Pruijn

Co-Founder

Prof. Dr. Ger Pruijn (1959) received his M.Sc. degree in chemistry from University of Nijmegen in 1984 and his PhD in 1989 at the University of Utrecht. In 2006 he became Full Professor of Biomolecular Chemistry at the Institute for Molecules and Materials of the Radboud University Nijmegen. His research is focused on autoimmunity molecular biology, in particular the auto-antigenic macromolecular complexes that play a role in nucleolar RNA metabolism and the role of post-translational modifications in autoimmunity.